1
|
Homma T, Okamoto M, Koharazawa R, Hayakawa M, Fushimi T, Tode C, Hirota Y, Osakabe N, Baba M, Suhara Y. Exploring Novel Vitamin K Derivatives with Anti-SARS-CoV-2 Activity. ACS Omega 2023; 8:42248-42263. [PMID: 38024673 PMCID: PMC10652723 DOI: 10.1021/acsomega.3c04175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 10/07/2023] [Accepted: 10/13/2023] [Indexed: 12/01/2023]
Abstract
From our compound library of vitamin K derivatives, we found that some compounds exhibited anti-SARS-CoV-2 activity in VeroE6/TMPRSS2 cells. The common structure of these compounds was menaquinone-2 (MK-2) with either the m-methylphenyl or the 1-naphthyl group introduced at the end of the side chain. Therefore, new vitamin K derivatives having more potent anti-SARS-CoV-2 activity were explored by introducing various functional groups at the ω-position of the side chain. MK-2 derivatives with a purine moiety showed the most potent antiviral activity among the derivatives. We also found that their mechanism of action was the inhibition of RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2. The chemical structures of our compounds were completely different from those of nucleic acid derivatives such as remdesivir and molnupiravir, clinically approved RdRp inhibitors for COVID-19 treatment, suggesting that our compounds may be effective against viruses resistant to these nucleic acid derivatives.
Collapse
Affiliation(s)
- Taiki Homma
- Department
of Bioscience and Engineering, College of Systems Engineering and
Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| | - Mika Okamoto
- Division
of Infection Control Research, Center for Advanced Science Research
and Promotion, Kagoshima University, Kagoshima 890-8580, Japan
| | - Ryohto Koharazawa
- Department
of Bioscience and Engineering, College of Systems Engineering and
Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| | - Mayu Hayakawa
- Department
of Bioscience and Engineering, College of Systems Engineering and
Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| | - Taiki Fushimi
- Functional
Control Systems, Graduate School of Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| | - Chisato Tode
- Instrumental
Analysis Center, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
| | - Yoshihisa Hirota
- Department
of Bioscience and Engineering, College of Systems Engineering and
Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
- Functional
Control Systems, Graduate School of Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| | - Naomi Osakabe
- Department
of Bioscience and Engineering, College of Systems Engineering and
Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
- Functional
Control Systems, Graduate School of Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| | - Masanori Baba
- Division
of Infection Control Research, Center for Advanced Science Research
and Promotion, Kagoshima University, Kagoshima 890-8580, Japan
| | - Yoshitomo Suhara
- Department
of Bioscience and Engineering, College of Systems Engineering and
Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
- Functional
Control Systems, Graduate School of Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan
| |
Collapse
|
2
|
Hosoda M, Takahashi M, Baba M, Oshino T, Moriya Y. P001 Scalp cooling system for breast cancer patients treated by adjuvant or neo-adjuvant chemotherapy. Breast 2023. [DOI: 10.1016/s0960-9776(23)00120-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
3
|
Kajiya T, Sawayama H, Arima E, Okamoto M, Baba M, Toyama M, Okuya K, Ozawa M, Atsuchi N, Nishi J, Suda Y. Novel RT-PCR Using Sugar Chain-Immobilized Gold-Nanoparticles Correlates Patients' Symptoms: The Follow-Up Study of COVID-19 Hospitalized Patients. Viruses 2022; 14:v14112577. [PMID: 36423185 PMCID: PMC9692348 DOI: 10.3390/v14112577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/11/2022] [Accepted: 11/14/2022] [Indexed: 11/22/2022] Open
Abstract
Background: The transmissible capacity and toxicity of SARS-CoV-2 variants are continually changing. We report here the follow-up study of hospitalized COVID-19 patients from 2020 to 2022. It is known that the PCR diagnosis for hospitalized patients sometimes causes confusion because of the incompatibility between their diagnosis and symptoms. We applied our sugar chain-immobilized gold-nanoparticles for the extraction and partial purification of RNA from specimens for quantitative RT-PCR assay and evaluated whether the results correlate with patients' symptoms. Methods and Results: Saliva specimens were taken from hospitalized patients with mild or moderate symptoms every early morning. At the time of RT-PCR diagnosis, two methods for the extraction and partial purification of RNA from the specimen were performed: a commonly used Boom (Qiagen) method and our original sugar chain-immobilized gold nanoparticle (SGNP) method. For symptoms, body temperature and oxygen saturation (SpO2) of patients were monitored every 4 h. Conclusions: It was clear that patients infected with the Delta variant needed more time to recover than those with the Omicron variant, and that the SGNP method showed more realistic correlation with the symptoms of patients compared with the common Qiagen method.
Collapse
Affiliation(s)
- Takashi Kajiya
- Clinical Research Center, Tenyoukai Central Hospital, 6-7 Izumi-cho, Kagoshima 892-0822, Japan
- Correspondence: (T.K.); (Y.S.); Tel./Fax: +81-99-226-8181 (T.K.); +81-99-285-8369 (Y.S.)
| | - Hayate Sawayama
- Laboratory of Collaborational Research for Glyco-Nanotechnology, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Eriko Arima
- Laboratory of Collaborational Research for Glyco-Nanotechnology, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Mika Okamoto
- Center for Advanced Science Research and Promotion, Kagoshima University, Kagoshima 890-0065, Japan
| | - Masanori Baba
- Center for Advanced Science Research and Promotion, Kagoshima University, Kagoshima 890-0065, Japan
| | - Masaaki Toyama
- Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima 890-8544, Japan
| | - Kosuke Okuya
- Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan
| | - Makoto Ozawa
- Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan
| | - Nobuhiko Atsuchi
- Clinical Research Center, Tenyoukai Central Hospital, 6-7 Izumi-cho, Kagoshima 892-0822, Japan
| | - Junichiro Nishi
- Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan
| | - Yasuo Suda
- Laboratory of Collaborational Research for Glyco-Nanotechnology, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
- Correspondence: (T.K.); (Y.S.); Tel./Fax: +81-99-226-8181 (T.K.); +81-99-285-8369 (Y.S.)
| |
Collapse
|
4
|
Baba M, Adali N. Analyse de survie des patients atteints de glioblastome au Maroc. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
5
|
Ukawa M, Endo R, Yagi H, Tomono T, Miyata K, Shigeno K, Tobita E, Uto T, Baba M, Sakuma S. Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms. Int J Pharm 2021; 613:121376. [PMID: 34915143 DOI: 10.1016/j.ijpharm.2021.121376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 11/24/2021] [Accepted: 12/08/2021] [Indexed: 11/29/2022]
Abstract
We have developed an aggregate of D-octaarginine immobilized at multiple points on a co-polymer of N-vinylacetamide and acrylic acid. Previous studies revealed that immunoglobulin G and A were induced when mice were inoculated with influenza virus antigens under coadministration with the D-octaarginine-immobilized polymers as a mucosal vaccine adjuvant. Infection experiments demonstrated that mice vaccinated with a mixture of inactivated influenza viruses and the polymers were protected from infection with mouse-adapted infectious viruses. In the present study, we investigated the mechanism on antigen delivery under mucosal vaccination using the polymers. Two-hour retention of fluorescein-labeled ovalbumin (F-OVA) on the nasal mucosa was observed when applied with the polymers; nevertheless F-OVA was eliminated less than 10 min under polymer-free conditions. F-OVA mixed with the polymers was vigorously taken up into murine dendritic cells. Electrophoresis and dynamic light scattering analysis indicated that OVA interacted with the polymers. The uptake of F-OVA was hardly ever inhibited by the addition of an excess amount of intact OVA. The results suggested that viral antigens were accumulated on the mucosa and delivered into dendritic cells under basolateral membranes via dendrites extending to the mucosal surface and/or subsequent to their permeation through epithelial cells, when they were coadministered with D-octaarginine-immobilized polymers.
Collapse
Affiliation(s)
- Masami Ukawa
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Rikito Endo
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Haruya Yagi
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Takumi Tomono
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Kohei Miyata
- Life Science Materials Laboratory, ADEKA Co., 7-2-34, Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Koichi Shigeno
- Life Science Materials Laboratory, ADEKA Co., 7-2-34, Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Etsuo Tobita
- Life Science Materials Laboratory, ADEKA Co., 7-2-34, Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Tomofumi Uto
- Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake Miyazaki 889-1692, Japan
| | - Masanori Baba
- Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, Kagoshima 890-8544, Japan.
| | - Shinji Sakuma
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan.
| |
Collapse
|
6
|
Zouari H, Dabert M, Asia L, Wong-Wah-Chung P, Baba M, Balan L, Israëli Y. Influence of in situ photo-induced silver nanoparticles on the ageing of acrylate materials. J Photochem Photobiol A Chem 2021. [DOI: 10.1016/j.jphotochem.2020.113112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Okamoto M, Chono H, Hidaka A, Toyama M, Mineno J, Baba M. Induction of E. coli-derived endonuclease MazF suppresses HIV-1 production and causes apoptosis in latently infected cells. Biochem Biophys Res Commun 2020; 530:597-602. [PMID: 32747090 DOI: 10.1016/j.bbrc.2020.07.103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Accepted: 07/22/2020] [Indexed: 10/23/2022]
Abstract
The current antiretroviral therapy cannot cure the patients infected with human immunodeficiency virus type 1 (HIV-1) due to the existence of latently infected cells capable of virus production from harboring proviral DNA. MazF is an ACA nucleotide sequence-specific endoribonuclease derived from Escherichia coli. The conditional expression of MazF by binding of HIV-1 Tat to the promoter region of a MazF-expression vector has previously been shown to selectively inhibit HIV-1 replication in acutely infected cells. The expression of MazF significantly suppressed tumor necrosis factor (TNF)-α-induced HIV-1 production and viral RNA expression in the HIV-1 latently infected cell line OM-10.1 transduced with the MazF-expression vector (OM-10.1/MFR). Moreover, the viability of OM-10.1/MFR cells decreased with increasing concentrations of TNF-α, whereas such decrease was not observed for HL-60 cells transduced with the MazF-expression vector (HL-60/MFR), the uninfected parental cell line of OM-10.1. TNF-α increased the expression of cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase in OM-10.1/MFR cells, indicating that the cell death was caused by the induction of apoptosis. TNF-α-induced expression of MazF mRNA was detected in OM-10.1/MFR but not HL-60/MFR cells, suggesting that TNF-α-induced apoptosis of latently infected cells was due to the expression of MazF. Thus, the anti-HIV-1 gene therapy using the MazF-expression vector may have potential for the cure of HIV-1 infection in combination with suitable latency reversing agents through reducing the size of latently infected cells without viral reactivation.
Collapse
Affiliation(s)
- Mika Okamoto
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan
| | | | - Akemi Hidaka
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan
| | | | - Masanori Baba
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan.
| |
Collapse
|
8
|
Yokota R, Hashimoto S, Watanabe I, Kishimoto S, Toyama M, Okamoto M, Yoshimitsu M, Ishitsuka K, Ito Y, Baba M. Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). Anticancer Res 2020; 40:4471-4479. [PMID: 32727777 DOI: 10.21873/anticanres.14452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Revised: 06/22/2020] [Accepted: 06/26/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Adult T-cell leukemia (ATL) is a hematological malignancy caused by infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity. MATERIALS AND METHODS In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay. RESULTS The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting other cells. CONCLUSION The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL.
Collapse
Affiliation(s)
- Riri Yokota
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Shun Hashimoto
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan
| | - Ikuko Watanabe
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan
| | - Satoshi Kishimoto
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Mika Okamoto
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Makoto Yoshimitsu
- Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Kenji Ishitsuka
- Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Yuji Ito
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| |
Collapse
|
9
|
Okamoto M, Toyama M, Baba M. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 182:104902. [PMID: 32739404 PMCID: PMC7392080 DOI: 10.1016/j.antiviral.2020.104902] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 07/24/2020] [Accepted: 07/27/2020] [Indexed: 12/21/2022]
Abstract
Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C-C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C-C chemokine receptor type 2b (CCR2b), thereby it has potent anti-inflammatory and immunomodulatory effects. CVC is currently under clinical trials in the patients for treatment of nonalcoholic steatohepatitis, in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis. In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 μM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Interestingly, the CCR5-specific antagonist maraviroc did not show any anti-SARS-CoV-2 activity. Although the mechanism of SARS-CoV-2 inhibition by CVC remains to be elucidated, CCR2b does not seem to be its target molecule. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Mika Okamoto
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan.
| |
Collapse
|
10
|
Samunuri R, Toyama M, Pallaka RS, Neeladri S, Jha AK, Baba M, Bal C. Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin. RSC Med Chem 2020; 11:597-601. [PMID: 33479662 DOI: 10.1039/d0md00059k] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Accepted: 04/22/2020] [Indexed: 12/16/2022] Open
Abstract
Modified carbocyclic nucleosides (4a-g) constituting 7-deazapurine, 4'-methyl, exocyclic double bond and 2',3'-hydroxy were synthesized. NOE and X-ray studies of 4c confirmed the α-configuration of 4'-methyl. The anti-HBV assay demonstrated 4e (IC50 = 3.4 μM) without notable cytotoxicity (CC50 = 87.5 μM) as a promising lead for future exploration.
Collapse
Affiliation(s)
- Ramakrishnamraju Samunuri
- Department of Chemistry , Birla Institute of Technology , Mesra , Ranchi , Jharkhand 835215 , India . .,Chemistry Services , GVK Biosciences Pvt. Ltd , IDA Nacharam , Hyderabad , India
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy , Joint Research Center for Human Retrovirus Infection , Kagoshima University , 8-35-1, Sakuragaoka , Kagoshima , 890-8544 , Japan
| | | | - Seshubabu Neeladri
- Chemistry Services , GVK Biosciences Pvt. Ltd , IDA Nacharam , Hyderabad , India
| | - Ashok Kumar Jha
- Chemistry Services , GVK Biosciences Pvt. Ltd , IDA Nacharam , Hyderabad , India
| | - Masanori Baba
- Division of Antiviral Chemotherapy , Joint Research Center for Human Retrovirus Infection , Kagoshima University , 8-35-1, Sakuragaoka , Kagoshima , 890-8544 , Japan
| | - Chandralata Bal
- Department of Chemistry , Birla Institute of Technology , Mesra , Ranchi , Jharkhand 835215 , India .
| |
Collapse
|
11
|
Furukawa Y, Hamada H, Kamikawaji K, Unoki T, Inoue H, Tashiro Y, Okamoto M, Baba M, Hashiguchi T. Successful treatment of an AIDS patient with prolonged Mycobacterium avium bacteremia, high HIV RNA, HBV infection, Kaposi's sarcoma and cytomegalovirus retinitis. J Infect Chemother 2020; 26:279-281. [DOI: 10.1016/j.jiac.2019.08.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Revised: 07/15/2019] [Accepted: 08/18/2019] [Indexed: 11/25/2022]
|
12
|
Matsutani H, Amano M, Izumi C, Baba M, Abe R, Hashiwada S, Kuwano K, Shimada M, Sakamoto J, Miyake M, Tamura T, Matsuo S. P1444 Occurrence and predictors of right ventricular dysfunction after pericardiocentesis. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background—The changes in cardiac function that occur after pericardiocentesis are unclear.Purpose—This study was performed to assess right ventricular (RV) and left ventricular (LV) function with echocardiography before and after pericardiocentesis.
Method and Results—In total, 19 consecutive patients who underwent pericardiocentesis for more than moderate pericardial effusion were prospectively enrolled from August 2015 to October 2017. Comprehensive transthoracic echocardiography was performed before, immediately after (within 3 hours), and 1 day after pericardiocentesis to investigate the changes in RV and LV function. RV dysfunction is defined as meeting three of the four criteria: a TAPSE of <17 mm, an S’ of <9.5 cm, an FAC of <35%, and an RV free wall longitudinal strain >−20%. The mean age of all patients was 72.6 ± 12.2 years. The changes of echocardiographic parameters related to RV function are shown in Table. After pericardiocentesis, RV inflow and outflow diameters increased and the parameters of RV function significantly decreased. These abnormal values or RV dysfunction remained at 1 day after pericardiocentesis. Conversely, no parameters of LV function parameters changed after pericardiocentesis. Of 19 patients, 13 patients showed RV dysfunction immediately after pericardiocentesis and 6 patients did not. RV free wall longitudinal strain before pericardiocentesis was higher in patients with post-procedural RV dysfunction (−18.9 ± 3.6%) than in those without (−28.4 ± 6.3%). ROC analysis revealed that a RV free wall longitudinal strain cut-off value of −23.0% had a sensitivity of 100% and a specificity of 83.3% for predicting the occurrence of RV dysfunction after pericardiocentesis (AUC = 0.910).
Conclusions—The occurrence of RV dysfunction after pericardiocentesis should be given more attention. Pre-existing RV dysfunction maybe related to the occurrence of RV dysfunction after pericardiocentesis.
Changes in RV function before and after Before Immediately after One day after P−value Basal right ventricular linear dimension (mm) 32.8 ± 5.0 37.1 ± 4.4† 33.6 ± 5.4 0.028 Mid-cavity right ventricular linear dimension (mm) 34.5 ± 4.6 38.8 ± 5.3† 37.0 ± 5.6 0.0504 Proximal right ventricular outflow diameter (mm) 30.2 ± 4.0 33.9 ± 3.5† 31.4 ± 3.9 0.014 TAPSE (mm) 20.0 ± 4.2 13.6 ± 4.3* 14.7 ± 3.9 <0.001 S" (cm/s) 12.6 ± 3.3 8.7 ± 2.4* 9.1 ± 2.4 <0.001 Fractional area change (%) 48.3 ± 5.9 37.8 ± 8.0* 40.0 ± 9.0 <0.001 Right ventricular free wall strain (%) −21.3 ± 6.3 −15.8 ± 6.7* −16.9 ± 5.2 0.036 Tricuspid regurgitation velocity peak (m/s) 2.41 ± 0.29 2.43 ± 0.25 2.34 ± 0.32 0.37
Collapse
Affiliation(s)
- H Matsutani
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - M Amano
- National Cerebral and Cardiovascular Center, Department of Cardiovascular Medicine, Osaka, Japan
| | - C Izumi
- National Cerebral and Cardiovascular Center, Department of Cardiovascular Medicine, Osaka, Japan
| | - M Baba
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - R Abe
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - S Hashiwada
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - K Kuwano
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - M Shimada
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| | - J Sakamoto
- Tenri Hospital, Department of Cardiology, Tenri, Japan
| | - M Miyake
- Tenri Hospital, Department of Cardiology, Tenri, Japan
| | - T Tamura
- Tenri Hospital, Department of Cardiology, Tenri, Japan
| | - S Matsuo
- Tenri Hospital, Department of Clinical Laboratory, Tenri, Japan
| |
Collapse
|
13
|
Tanishita S, Ukawa M, Tomono T, Yoshida Y, Tsujioka T, Miyata K, Tobita E, Uto T, Baba M, Sakuma S. Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses. Bioconjug Chem 2019; 30:3028-3037. [PMID: 31738536 DOI: 10.1021/acs.bioconjchem.9b00644] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Mucosal vaccination, which secretion of immunoglobulin A (IgA) on the mucosa is accompanied by induction of immunoglobulin G (IgG) in the blood, is one of the most effective ways to circumvent influenza epidemics caused by incorrect prediction of epidemic viral strains or viral mutation. Secreted IgA is expected to prevent hosts from being infected with heterologous viruses because this antibody cross-reacts to strains other than those used for immunization. Our previous mouse experiments revealed that intranasal IgA with cross-reactivity was induced through nasal inoculation with inactivated whole viral particles of the H1N1 A/New Caledonia/20/99 IVR116 (NCL) strain in the presence of hyaluronic acid modified with tetraglycine-l-octaarginine. In the present study, heterologous influenza virus challenge was performed to validate a potential of the hyaluronic acid derivative as a mucosal adjuvant with cross-protective abilities. Serious weight loss was observed when mice were nasally inoculated with inactivated NCL viruses alone and subsequently exposed to mouse-adapted infectious viruses of the H1N1 A/Puerto Rico/8/34 (PR8) strain. The symptom associated with virus infection was hardly ever observed for mice inoculated with a mixture of the viral antigens and tetraglycine-l-octaarginine-linked hyaluronic acid, presumably due to high induction of IgG and IgA capable of cross-reacting to PR8 viruses. Less proliferation of PR8 viruses in those mice was also supported by an insignificant elevation of antibody levels through virus exposure. Our polysaccharide derivative enabled hosts to acquire adaptive immunity with cross-protective abilities against heterologous virus infection.
Collapse
Affiliation(s)
- Sohei Tanishita
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata, Osaka 573-0101 , Japan
| | - Masami Ukawa
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata, Osaka 573-0101 , Japan
| | - Takumi Tomono
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata, Osaka 573-0101 , Japan
| | - Yuki Yoshida
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata, Osaka 573-0101 , Japan
| | - Takumi Tsujioka
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata, Osaka 573-0101 , Japan
| | - Kohei Miyata
- Life Science Materials Laboratory , ADEKA Company, Limited , 7-2-34, Higashiogu , Arakawa-ku, Tokyo 116-8553 , Japan
| | - Etsuo Tobita
- Life Science Materials Laboratory , ADEKA Company, Limited , 7-2-34, Higashiogu , Arakawa-ku, Tokyo 116-8553 , Japan
| | - Tomofumi Uto
- Faculty of Medicine , University of Miyazaki , Kihara 5200, Kiyotake , Miyazaki 889-1692 , Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection , Kagoshima University , 8-35-1, Sakuragaoka , Kagoshima 890-8544 , Japan
| | - Shinji Sakuma
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata, Osaka 573-0101 , Japan
| |
Collapse
|
14
|
Toyama M, Sakakibara N, Takeda M, Okamoto M, Watashi K, Wakita T, Sugiyama M, Mizokami M, Ikeda M, Baba M. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. Virus Res 2019; 271:197677. [PMID: 31376401 DOI: 10.1016/j.virusres.2019.197677] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2019] [Revised: 07/31/2019] [Accepted: 07/31/2019] [Indexed: 02/07/2023]
Abstract
Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside/nucleotides analogs. They are potent inhibitors of HBV DNA polymerase, which also functions as reverse transcriptase. Although nucleoside/nucleotide analogs efficiently suppress HBV replication in liver cells, they cannot eradicate HBV DNA from liver cells and cure the disease. Therefore, it is still mandatory to identify and develop effective inhibitors that target a step other than reverse transcription in the viral replication cycle. HBV capsid assembly is a critical step for viral replication and an attractive target for inhibition of HBV replication. We conducted in silico screening of compounds expected to bind to the HBV capsid dimer-dimer interaction site. The selected compounds were further examined for their anti-HBV activity in vitro. Among the test compounds, novel pyrimidotriazine derivatives were found to be selective inhibitors of HBV replication in HepG2.2.15.7 cells. Among the compounds, 2-[(2,3-dichlorophenyl)amino]-4-(4-tert-butylphenyl)-8-methyl-4H,9H-pyrimido[1,2-a][1,3,5]triazin-6-one was the most active against HBV replication. Studies on its mechanism of action revealed that the compound interfered with HBV capsid assembly determined by a cell-free capsid assembly system. Thus, the pyrimidotriazine derivatives are considered to be potential leads for novel HBV capsid assembly inhibitors.
Collapse
Affiliation(s)
- Masaaki Toyama
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Norikazu Sakakibara
- Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki, Japan
| | - Midori Takeda
- Division of Biological Information Technology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Mika Okamoto
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Koichi Watashi
- Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
| | - Takaji Wakita
- Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
| | - Masaya Sugiyama
- The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan
| | - Masashi Mizokami
- The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan
| | - Masanori Ikeda
- Division of Biological Information Technology, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.
| |
Collapse
|
15
|
Ukawa M, Tanishita S, Yagi H, Yoshida Y, Tomono T, Shigeno K, Tobita E, Uto T, Baba M, Sakuma S. Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination. Mol Pharm 2019; 16:1105-1118. [PMID: 30715891 DOI: 10.1021/acs.molpharmaceut.8b01110] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
We have been investigating the potential use of polymers modified with cell-penetrating peptides as an adjuvant for mucosal vaccination and have already developed nondegradable poly( N-vinylacetamide- co-acrylic acid) (PNVA- co-AA) with which d-octaarginine, a typical cell-penetrating peptide, was grafted. Our previous murine infection experiments demonstrated that immunoglobulin G (IgG) and immunoglobulin A (IgA) were induced in systemic circulation and secreted on nasal mucosa, respectively, through 4-time nasal inoculations with a mixture of influenza viral antigens and d-octaarginine-linked PNVA- co-AA at 7-day intervals, and that immunized mice were perfectly protected from homologous virus infection. In the present study, we designed novel biodegradable polymers bearing cell-penetrating peptides from a perspective of clinical application. Hyaluronic acid whose glucuronic acid was modified with tetraglycine-l-octaarginine at a monosaccharide unit ratio of 30% was successfully developed. The hyaluronic acid derivative exhibited adjuvant activities identical to PNVA- co-AA bearing either d-octaarginine or tetraglycine-d-octaarginine under the above-mentioned inoculation schedule. We further found that there was no difference in humoral immunity between the 4-time inoculations at 7-day intervals and the 2-time inoculations at 28-day intervals. Intranasal IgA induced through the latter schedule with a smaller number of inoculations, which is clinically practical, exhibited cross-reactivity beyond the subtype of viral strains. In vitro toxicity studies demonstrated that the hyaluronic acid derivative was much less toxic than the corresponding PNVA- co-AA derivatives, and that both the polymers and their metabolites did not exhibit genotoxicity. Our results suggested that tetraglycine-l-octaarginine-linked hyaluronic acid would be a clinically valuable and safe adjuvant for mucosal vaccination.
Collapse
Affiliation(s)
- Masami Ukawa
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata , Osaka 573-0101 , Japan
| | - Sohei Tanishita
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata , Osaka 573-0101 , Japan
| | - Haruya Yagi
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata , Osaka 573-0101 , Japan
| | - Yuki Yoshida
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata , Osaka 573-0101 , Japan
| | - Takumi Tomono
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata , Osaka 573-0101 , Japan
| | - Koichi Shigeno
- Life Science Materials Laboratory , ADEKA Co. , 7-2-34, Higashiogu , Arakawa-ku , Tokyo 116-8553 , Japan
| | - Etsuo Tobita
- Life Science Materials Laboratory , ADEKA Co. , 7-2-34, Higashiogu , Arakawa-ku , Tokyo 116-8553 , Japan
| | - Tomofumi Uto
- Faculty of Medicine , University of Miyazaki , Kihara 5200, Kiyotake , Miyazaki 889-1692 , Japan
| | - Masanori Baba
- Center for Chronic Viral Diseases , Kagoshima University , 8-35-1, Sakuragaoka , Kagoshima 890-8544 , Japan
| | - Shinji Sakuma
- Faculty of Pharmaceutical Sciences , Setsunan University , 45-1, Nagaotoge-cho , Hirakata , Osaka 573-0101 , Japan
| |
Collapse
|
16
|
Kumamoto H, Imoto S, Amano M, Kuwata-Higashi N, Baba M, Mitsuya H, Odanaka Y, Shimbara Matsubayashi S, Tanaka H, Haraguchi K. Synthesis, Anti-HBV, and Anti-HIV Activities of 3'-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. ACS Med Chem Lett 2018; 9:1211-1216. [PMID: 30613328 DOI: 10.1021/acsmedchemlett.8b00374] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 11/09/2018] [Indexed: 12/18/2022] Open
Abstract
Synthesis of 3'-halogeno analogues (5a-d) of 9-[c-4,t-5-bis(hydroxymethyl)-cyclopent-2-en-r-1-yl]-9H-adenine (BCA, 3) was accomplished by means of dual utilization of the vinyl sulfone functional moieties in both 10 and 16 utilizing a SN2' conjugate-addition reaction and a sulfur-extrusive stannylation, respectively. Evaluation of the antiviral activities of 5a-d revealed that introduction of a halogeno-substituent into the 3'-position of (-)-BCA diminished its anti-HIV-1 activity but increased the inhibitory activity for the reverse transcriptase of HBV in that the 3'-fluorinated BCA 5d exhibited the highest activity without significant cytotoxicity.
Collapse
Affiliation(s)
- Hiroki Kumamoto
- Nihon Pharmaceutical University, 10281 Komuro, Inamachi, Kita-adachi-gun, Saitama 362-0806, Japan
| | - Shuhei Imoto
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Kumamoto 860-0082, Japan
| | - Masayuki Amano
- Departments of Infectious Diseases and Hematology, Kumamoto University School of Medicine, Kumamoto 860-8556, Japan
| | - Nobuyo Kuwata-Higashi
- Clinical Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan
| | - Hiroaki Mitsuya
- Departments of Infectious Diseases and Hematology, Kumamoto University School of Medicine, Kumamoto 860-8556, Japan
- Clinical Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan
- Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Yuki Odanaka
- School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
| | | | - Hiromichi Tanaka
- School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
| | - Kazuhiro Haraguchi
- Nihon Pharmaceutical University, 10281 Komuro, Inamachi, Kita-adachi-gun, Saitama 362-0806, Japan
| |
Collapse
|
17
|
Tárkányi F, Ditrói F, Takács S, Csikai J, Hermanne A, Uddin MS, Baba M. Production routes of 107,109Cd radioisotopes via charged particle induced nuclear reactions. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-6226-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Okamoto M, Hidaka A, Toyama M, Baba M. Galectin-3 is involved in HIV-1 expression through NF-κB activation and associated with Tat in latently infected cells. Virus Res 2018; 260:86-93. [PMID: 30481548 DOI: 10.1016/j.virusres.2018.11.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Revised: 09/12/2018] [Accepted: 11/23/2018] [Indexed: 12/13/2022]
Abstract
Galectin-3 (Gal-3) is involved in many biological processes and pathogenesis of diseases in part through nuclear factor (NF)-κB activation. We demonstrated that Gal-3 expression was significantly induced by tumor necrosis factor (TNF)-α or phorbol 12-myristate 13-acetate in OM-10.1 and ACH-2 cells, which are considered as a model of HIV-1 latently infected cells. The expression of Gal-3 was also associated with their viral production. However, the induction of Gal-3 by TNF-α was not observed in their uninfected parental cells. Knockdown of Gal-3 resulted in the suppression of NF-κB activation and HIV-1 replication in the latently infected cells. The expression level of Gal-3 was highly correlated with that of HIV-1 Tat in the latently infected cells stimulated with TNF-α. Furthermore, colocalization and possible interaction of Gal-3 and Tat were observed in the stimulated cells. These results suggent that Gal-3 expression is closely correlated with HIV-1 expression in latently infected cells through NF-κB activation and the interaction with Tat.
Collapse
Affiliation(s)
- Mika Okamoto
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, 890-8544, Japan
| | - Akemi Hidaka
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, 890-8544, Japan
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, 890-8544, Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, 890-8544, Japan.
| |
Collapse
|
19
|
Muchima K, Todaka T, Shinchi H, Sato A, Tazoe A, Aramaki R, Kakitsubata Y, Yokoyama R, Arima N, Baba M, Wakao M, Ito Y, Suda Y. Development of sugar chain-binding single-chain variable fragment antibody to adult T-cell leukemia cells using glyco-nanotechnology and phage display method. J Biochem 2018; 163:281-291. [PMID: 29351623 DOI: 10.1093/jb/mvy005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 10/06/2017] [Indexed: 11/12/2022] Open
Abstract
Adult T-cell leukemia (ATL) is an intractable blood cancer caused by the infection of human T-cell leukemia virus type-1, and effective medical treatment is required. It is known that the structure and expression levels of cell surface sugar chains vary depending on cell states such as inflammation and cancer. Thus, it is expected that the antibody specific for ATL cell surface sugar chain would be an effective diagnostic tool and a strong candidate for the development of an anti-ATL drug. Here, we developed a stable sugar chain-binding single-chain variable fragment antibody (scFv) that can bind to ATL cells using a fibre-type Sugar Chip and phage display method. The fiber-type Sugar Chips were prepared using O-glycans released from ATL cell lines. The scFv-displaying phages derived from human B cells (diversity: 1.04 × 108) were then screened using the fiber-type Sugar Chips, and an O-glycan-binding scFv was obtained. The flow cytometry analysis revealed that the scFv predominantly bound to ATL cell lines. The sugar chain-binding properties of the scFv was evaluated by array-type Sugar Chip immobilized with a library of synthetic glycosaminoglycan disaccharide structures. Highly sulphated disaccharide structures were found to have high affinity to scFv.
Collapse
Affiliation(s)
- Kaname Muchima
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Taro Todaka
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Hiroyuki Shinchi
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Ayaka Sato
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Arisa Tazoe
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Rikiya Aramaki
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Yuhei Kakitsubata
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Risa Yokoyama
- Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima 890-8544, Japan
| | - Naomichi Arima
- SUDx-Biotec Corporation, Shiroyama 1-21-40, Kagoshima 890-0013, Japan
| | - Masanori Baba
- SUDx-Biotec Corporation, Shiroyama 1-21-40, Kagoshima 890-0013, Japan
| | - Masahiro Wakao
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Yuji Ito
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan
| | - Yasuo Suda
- Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan.,Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima 890-8544, Japan
| |
Collapse
|
20
|
Gauci MO, Bonnevialle N, Moineau G, Baba M, Walch G, Boileau P. Anatomical total shoulder arthroplasty in young patients with osteoarthritis: all-polyethylene versus metal-backed glenoid. Bone Joint J 2018; 100-B:485-492. [PMID: 29629579 DOI: 10.1302/0301-620x.100b4.bjj-2017-0495.r2] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Aims Controversy about the use of an anatomical total shoulder arthroplasty (aTSA) in young arthritic patients relates to which is the ideal form of fixation for the glenoid component: cemented or cementless. This study aimed to evaluate implant survival of aTSA when used in patients aged < 60 years with primary glenohumeral osteoarthritis (OA), and to compare the survival of cemented all-polyethylene and cementless metal-backed glenoid components. Materials and Methods A total of 69 consecutive aTSAs were performed in 67 patients aged < 60 years with primary glenohumeral OA. Their mean age at the time of surgery was 54 years (35 to 60). Of these aTSAs, 46 were undertaken using a cemented polyethylene component and 23 were undertaken using a cementless metal-backed component. The age, gender, preoperative function, mobility, premorbid glenoid erosion, and length of follow-up were comparable in the two groups. The patients were reviewed clinically and radiographically at a mean of 10.3 years (5 to 12, sd 26) postoperatively. Kaplan-Meier survivorship analysis was performed with revision as the endpoint. Results A total of 26 shoulders (38%) underwent revision surgery: ten (22%) in the polyethylene group and 16 (70%) in the metal-backed group (p < 0.0001). At 12 years' follow-up, the rate of implant survival was 74% (sd 0.09) for polyethylene components and 24% (sd 0.10) for metal-backed components (p < 0.0002). Glenoid loosening or failure was the indication for revision in the polyethylene group, whereas polyethylene wear with metal-on-metal contact, instability, and insufficiency of the rotator cuff were the indications for revision in the metal-backed group. Preoperative posterior subluxation of the humeral head with a biconcave/retroverted glenoid (Walch B2) had an adverse effect on the survival of a metal-backed component. Conclusion The survival of a cemented polyethylene glenoid component is three times higher than that of a cementless metal-backed glenoid component ten years after aTSA in patients aged < 60 years with primary glenohumeral OA. Patients with a biconcave (B2) glenoid have the highest risk of failure. Cite this article: Bone Joint J 2018;100-B:485-92.
Collapse
Affiliation(s)
- M O Gauci
- Institut Universitaire Locomoteur et du Sport, Hôpital Pasteur 2 and Université Nice-Sophia Antipolis, Nice Cedex 1, France
| | - N Bonnevialle
- Centre Hospitalier Universitaire de Toulouse-Purpan, Toulouse, France
| | - G Moineau
- Clinique Pasteur-Lanroze, Brest, France
| | - M Baba
- Sydney Adventist Hospital, Wahroonga, New South Wales, Australia
| | - G Walch
- Centre Médical Santy, Lyon, France
| | - P Boileau
- Institut Universitaire Locomoteur et du Sport, Hôpital Pasteur 2 and Université Nice-Sophia Antipolis, Nice Cedex 1, France
| |
Collapse
|
21
|
Mohri K, Miyata K, Egawa T, Tanishita S, Endo R, Yagi H, Ukawa M, Ochiai K, Hiwatari KI, Tsubaki K, Shigeno K, Tobita E, Uto T, Baba M, Sakuma S. Effects of the Chemical Structures of Oligoarginines Conjugated to Biocompatible Polymers as a Mucosal Adjuvant on Antibody Induction in Nasal Cavities. Chem Pharm Bull (Tokyo) 2018; 66:375-381. [PMID: 29607903 DOI: 10.1248/cpb.c17-00834] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We have been investigating the potential of oligoarginine-linked polymers as an adjuvant for mucosal vaccination that induces immunoglobulin G (IgG) in systemic circulation and immunoglobulin A (IgA) secreted on the mucosa. Our latest infection experiments demonstrated that mice immunized nasally with a mixture of inactivated influenza viruses and poly(N-vinylacetamide-co-acrylic acid) (PNVA-co-AA) modified with D-octaarginine were perfectly protected from homologous virus infection. On the contrary, virus infection was observed in mice immunized with the antigen alone. This difference was presumably due to insignificant induction of secreted IgA on the nasal mucosa in the latter mice. Since it was unclear whether the current induction level was sufficient for heterologous virus infection, we evaluated the effects of the chemical structures of oligoarginines conjugated to PNVA-co-AA on induction of intranasal IgA. The number and optical activity of the arginine residues and the degree of modification with oligoarginines in the polymer backbone were listed as a factor that would influence IgA induction. Mouse experiments revealed that maximization of the modification resulted in an increase in adjuvant activities of oligoarginine-linked polymers most effectively. Glycine segments inserted between oligoarginines and the polymer backbone were a prerequisite for the maximization. The highest IgA level was observed when antigens were coadministered with diglycine-D-octaarginine-linked PNVA-co-AA.
Collapse
Affiliation(s)
- Kohta Mohri
- Faculty of Pharmaceutical Sciences, Setsunan University
| | - Kohei Miyata
- Faculty of Pharmaceutical Sciences, Setsunan University.,Life Science Materials Laboratory, ADEKA Co
| | - Tomomi Egawa
- Faculty of Pharmaceutical Sciences, Setsunan University
| | | | - Rikito Endo
- Faculty of Pharmaceutical Sciences, Setsunan University
| | - Haruya Yagi
- Faculty of Pharmaceutical Sciences, Setsunan University
| | - Masami Ukawa
- Faculty of Pharmaceutical Sciences, Setsunan University
| | | | | | | | | | | | | | - Masanori Baba
- Center for Chronic Viral Diseases, Kagoshima University
| | - Shinji Sakuma
- Faculty of Pharmaceutical Sciences, Setsunan University
| |
Collapse
|
22
|
Ishida N, Hatanaka Y, Baba M, Hagio K, Okada H, Hatanaka KC, Matsuno Y, Yamashita H. Abstract P4-08-07: PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive, HER2-negative early breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Endocrine therapy is the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. We recently reported that approximately two-thirds of patients who relapsed within 5 years had received anthracyclins and/or taxanes as adjuvant or neoadjuvant chemotherapy in addition to adjuvant endocrine therapy. New strategies, such as signal transduction inhibitors together with endocrine therapy are required to improve survival. PIK3CA mutations are detected in almost 40% of early ER-positive breast cancers, and are therefore the most frequent genetic alterations in this subtype. PIK3CA mutation status is reported to affect activation of AKT and ERα. Moreover, recent studies demonstrate that patients had a better prognosis when tumors expressed ER, androgen receptor (AR), and vitamin D receptor (VDR).
Methods: Expression of AR and VDR, phosphorylation of AKT serine (Ser) 473 (AKT phospho-Ser473) and ERα Ser167 (ERα phospho-Ser167) were examined by immunohistochemistry in ER-positive, HER2-negative early breast cancer tissues. Seventeen mutations in exons 1, 4, 7, 9, and 20 of the PIK3CA gene were detected in genomic DNA extracted from formalin-fixed paraffin-embedded tumor blocks. Correlations between these biological markers and clinicopathological factors and prognosis were analyzed separately in pre- and postmenopausal women.
Results: Levels of AKT phospho-Ser473 were significantly higher in premenopausal women (n = 62) than in postmenopausal women (n = 152) (P < 0.0001 and P = 0.014, respectively). In contrast, expression levels of AR were significantly higher in postmenopausal women than in premenopausal women (P < 0.0001). In premenopausal women, 26 tumors (43%) had a single mutation of PIK3CA gene, and 3 tumors (5%) had mutations at two sites. In postmenopausal women, 64 tumors (44%) had a single PIK3CA mutation, 6 tumors (4%) had mutations at two sites, and one tumor (1%) had mutations at three sites. In premenopausal women, wild type PIK3CA was associated with smaller tumor size, higher ER expression levels, and lower AR expression levels when compared with women in the same cohort with PIK3CA mutant tumors. In postmenopausal women, patients with PIK3CA wild-type tumors had higher Ki67 labeling index, higher AKT phospho-Ser473, and lower ERα phospho-Ser167 when compared to patients with PIK3CA mutant tumors. Postmenopausal women with PIK3CA wild-type tumors had significantly worse disease-free survival than patients with PIK3CA mutant tumors (P = 0.007). In contrast, PIK3CA mutation status was not correlated with survival in premenopausal women. Low levels of AKT phospho-Ser473 and high levels of ERα phospho-Ser167 were strongly associated with increased disease-free survival in postmenopausal women (P = 0.016 and P = 0.0016, respectively).
Conclusion: ERα activation, in addition to PIK3CA mutation, may be biomarkers for highly endocrine-responsive tumors. This would facilitate the selection of postmenopausal ER-positive breast cancer patients who are likely to benefit from endocrine therapy alone from those who are not.
Citation Format: Ishida N, Hatanaka Y, Baba M, Hagio K, Okada H, Hatanaka KC, Matsuno Y, Yamashita H. PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive, HER2-negative early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-08-07.
Collapse
Affiliation(s)
- N Ishida
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - Y Hatanaka
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - M Baba
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - K Hagio
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - H Okada
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - KC Hatanaka
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - Y Matsuno
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| | - H Yamashita
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan
| |
Collapse
|
23
|
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, Sabet A, George K, Roberts L, Carne R, Blum S, Henderson R, Van Damme P, Demeestere J, Larue S, D'Amour C, Bril V, Breiner A, Kunc P, Valis M, Sussova J, Kalous T, Talab R, Bednar M, Toomsoo T, Rubanovits I, Gross-Paju K, Sorro U, Saarela M, Auranen M, Pouget J, Attarian S, Le Masson G, Wielanek-Bachelet A, Desnuelle C, Delmont E, Clavelou P, Aufauvre D, Schmidt J, Zschuentssch J, Sommer C, Kramer D, Hoffmann O, Goerlitz C, Haas J, Chatzopoulos M, Yoon R, Gold R, Berlit P, Jaspert-Grehl A, Liebetanz D, Kutschenko A, Stangel M, Trebst C, Baum P, Bergh F, Klehmet J, Meisel A, Klostermann F, Oechtering J, Lehmann H, Schroeter M, Hagenacker T, Mueller D, Sperfeld A, Bethke F, Drory V, Algom A, Yarnitsky D, Murinson B, Di Muzio A, Ciccocioppo F, Sorbi S, Mata S, Schenone A, Grandis M, Lauria G, Cazzato D, Antonini G, Morino S, Cocito D, Zibetti M, Yokota T, Ohkubo T, Kanda T, Kawai M, Kaida K, Onoue H, Kuwabara S, Mori M, Iijima M, Ohyama K, Baba M, Tomiyama M, Nishiyama K, Akutsu T, Yokoyama K, Kanai K, van Schaik I, Eftimov F, Notermans N, Visser N, Faber C, Hoeijmakers J, Rejdak K, Chyrchel-Paszkiewicz U, Casanovas Pons C, Alberti Aguiló M, Gamez J, Figueras M, Marquez Infante C, Benitez Rivero S, Lunn M, Morrow J, Gosal D, Lavin T, Melamed I, Testori A, Ajroud-Driss S, Menichella D, Simpson E, Chi-Ho Lai E, Dimachkie M, Barohn R, Beydoun S, Johl H, Lange D, Shtilbans A, Muley S, Ladha S, Freimer M, Kissel J, Latov N, Chin R, Ubogu E, Mumfrey S, Rao T, MacDonald P, Sharma K, Gonzalez G, Allen J, Walk D, Hobson-Webb L, Gable K. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17:35-46. [DOI: 10.1016/s1474-4422(17)30378-2] [Citation(s) in RCA: 130] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/28/2017] [Accepted: 10/02/2017] [Indexed: 10/18/2022]
|
24
|
Baba M, Toyama M, Sakakibara N, Okamoto M, Arima N, Saijo M. Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors. Antivir Chem Chemother 2017; 25:83-89. [PMID: 29096526 PMCID: PMC5890513 DOI: 10.1177/2040206617740303] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Aims Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease. SFTS is epidemic in Asia, and its fatality rate is around 30% in Japan. The causative virus severe fever with thrombocytopenia syndrome virus (SFTSV) is a phlebovirus of the family Phenuiviridae (the order Bunyavirales). Although effective treatments are required, there are no antiviral agents currently approved for clinical use. Ribavirin and favipiravir were examined for their anti-SFTSV activity and found to be selective inhibitors of SFTSV replication in vitro. However, their activity was not sufficient. Therefore, it is mandatory to identify novel compounds active against SFTSV. To this end, we have established a safe and rapid assay system for screening selective inhibitors of SFTSV. Methods The virus was isolated from SFTS patients treated in Kagoshima University Hospital. Vero cells were infected with SFTSV and incubated in the presence of various concentrations of test compounds. After three days, the cells were examined for their intracellular viral RNA levels by real-time reverse transcription-PCR without extracting viral RNA. The cytotoxicity of test compounds was determined by a tetrazolium dye method. Results Among the test compounds, the antimalarial agent amodiaquine was identified as a selective inhibitor of SFTSV replication. Its 50% effective concentration (EC50) and cytotoxic concentration (CC50) were 19.1 ± 5.1 and >100 µM, respectively. The EC50 value of amodiaquine was comparable to those of ribavirin and favipiravir. Conclusion Amodiaquine is considered to be a promising lead of novel anti-SFTSV agents, and evaluating the anti-SFTSV activity of its derivatives is in progress.
Collapse
Affiliation(s)
- Masanori Baba
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima, University, Kagoshima, Japan
| | - Masaaki Toyama
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima, University, Kagoshima, Japan
| | - Norikazu Sakakibara
- 2 Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, Sanuki, Japan
| | - Mika Okamoto
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima, University, Kagoshima, Japan
| | - Naomichi Arima
- 3 Division of Hematology and Immunology, Center for Chronic Viral Diseases, Kagoshima, University, Kagoshima, Japan
| | - Masayuki Saijo
- 4 Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan
| |
Collapse
|
25
|
Oshiro T, Baba M, Fujita M, Kaneko Y, Takeda S, Hirano R, Mawatari K, Ishibashi Y, Miyabayashi I. The association for knowledge for the effect of respiratory infection, preventive action, and prevention of exacerbation in patients with COPD. Respir Med 2017. [DOI: 10.1016/j.rmed.2017.07.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Baba M, Aikou T, Natsugoe S, Kusano C, Shimada M, Nakano S, Fukumoto T, Yoshinaka H. Quality of life following esophagectomy with three-field lymphadenectomy for carcinoma, focusing on its relationship to vocal cord palsy. Dis Esophagus 2017; 11:28-34. [PMID: 29040479 DOI: 10.1093/dote/11.1.28] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
To clarify the quality of life of patients who underwent esophagectomy for carcinoma by right thoracotomy, laparotomy and cervical anastomosis, 116 patients who were cancer free at the time of mailing a questionnaire were analyzed. A significant decrease in vital capacity for 3 years postoperatively, as well as in the percentage of ideal body weight, between 3 and 5 years were observed in 57 patients with three-field lymphadenectomy. Patients' quality of life undergoing three-field dissection was worse than those with less radical lymphadenectomy (59 cases) in terms of the performance status and difficulty in talking at 60 months or more postoperatively. Around 20% of all patients reported severe hoarseness due to permanent recurrent nerve paralysis, resulting in poor quantity of food intake at 24 months or less postoperatively and restricted daily activity and difficulty in talking at 60 months or more after the operation. When a patient suffers from vocal cord insufficiency caused by permanent paralysis of the recurrent nerve, early treatment before discharge from the hospital should be performed to improve the quality of life of such a patient.
Collapse
Affiliation(s)
- M Baba
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - T Aikou
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - S Natsugoe
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - C Kusano
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - M Shimada
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - S Nakano
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - T Fukumoto
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| | - H Yoshinaka
- First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan
| |
Collapse
|
27
|
Baba M, Suzuki C, Tomiyama M. Five-year prospective study on development of diabetic foot with a severity staging system of diabetic neuropathy by nerve conduction study. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Suzuki C, Kon T, Funamizu Y, Ueno T, Haga R, Nishijima H, Arai A, Nunomura J, Tomiyama M, Baba M, Mizukami H, Yagihashi S. Loss of intraepidermal nerve fibers in Guillan-Barre syndrome. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Tomiyama M, Ueno T, Nishijima H, Kon T, Funamizu Y, Haga R, Arai A, Suzuki C, Nunomura J, Baba M. Driving license and car accident in patients with Parkinson’s disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Kon T, Suzuki C, Hotta R, Nukada H, Baba M, Tomiyama M. Nerve conduction study for diagnosing injury in the superficial radial nerve. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3607] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Uto T, Akagi T, Toyama M, Akashi M, Baba M. Induction of Innate and Adaptive Immunity with Polyion Complex Nanoparticle Adjuvant Carrying Human Immunodeficiency Virus Type-1 gp120. J Biomed Nanotechnol 2017. [DOI: 10.1166/jbn.2017.2399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
32
|
Affiliation(s)
- V. M. Maslov
- Joint Institute for Nuclear and Energy Research 220109, Minsk-Sosny, Belarus
| | - Yu. V. Porodzinskij
- Joint Institute for Nuclear and Energy Research 220109, Minsk-Sosny, Belarus
| | - M. Baba
- Tohoku University, Cyclotron and Radioisotope Center, Sendai, Japan
| | - A. Hasegawa
- Japan Atomic Energy Research Institute, Department of Nuclear Energy System Tokai Research Establishment, Tokai-mura, Naka-gun, Ibaraki-ken, Japan
| |
Collapse
|
33
|
Aoki T, Baba M, Yonai S, Kawata N, Hagiwara M, Miura T, Nakamura T. Measurement of Differential Thick-Target Neutron Yields of C, Al, Ta, W(p,xn) Reactions for 50-MeV Protons. NUCL SCI ENG 2017. [DOI: 10.13182/nse04-a2403] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Aoki
- Tohoku University, Cyclotron and Radioisotope Center Aramaki, Sendai 980-8578, Japan
| | - M. Baba
- Tohoku University, Cyclotron and Radioisotope Center Aramaki, Sendai 980-8578, Japan
| | - S. Yonai
- Tohoku University, Graduate School of Engineering Sendai 980-8578, Japan
| | - N. Kawata
- Tohoku University, Cyclotron and Radioisotope Center Aramaki, Sendai 980-8578, Japan
| | - M. Hagiwara
- Tohoku University, Cyclotron and Radioisotope Center Aramaki, Sendai 980-8578, Japan
| | - T. Miura
- Tohoku University, Cyclotron and Radioisotope Center Aramaki, Sendai 980-8578, Japan
| | - T. Nakamura
- Tohoku University, Graduate School of Engineering Sendai 980-8578, Japan
| |
Collapse
|
34
|
Hagiwara M, Itoga T, Kawata N, Hirabayashi N, Oishi T, Yamauchi T, Baba M, Sugimoto M, Muroga T. Measurement of Neutron Emission Spectra in Li(d,xn) Reaction with Thick and Thin Targets for 40-MeV Deuterons. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-a1081] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Hagiwara
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - T. Itoga
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - N. Kawata
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - N. Hirabayashi
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - T. Oishi
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - T. Yamauchi
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - M. Baba
- Tohoku University Cyclotron and Radioisotope Center, Sendai 980-8578, Japan
| | - M. Sugimoto
- Japan Atomic Energy Research Institute, Tokai-mura, Ibaraki 319-1195, Japan
| | - T. Muroga
- National Institute for Fusion Science, Oroshi-cho, Toki, Gifu 509-5292, Japan
| |
Collapse
|
35
|
Otsubo R, Hirakawa H, Oikawa M, Inamasu E, Baba M, Matsumoto M, Yano H, Kinoshita N, Abe K, Fukuoka J, Nagayasu T. Abstract P2-01-31: Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-01-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The semi-dry dot-blot (SDB) method is a diagnostic procedure for detecting lymph node (LN) metastases. Metastases are confirmed by the presence of cytokeratin (CK) in lavage fluid of sectioned LNs that contain anti-pancytokeratin antibody, based on the theory that epithelial components such as CK are not found in normal LNs. We evaluated two novel SDB kits that use the newly developed anti-CK19 antibody for diagnosing LN metastases in breast cancer.
Methods: We obtained 159 LNs dissected from 93 breast cancer patients from July 2013 to December 2015 at Nagasaki University Hospital, including 38 dissected axillary LNs and 121 sentinel LNs, sliced at 2-mm intervals and washed with phosphate-buffered saline. The suspended cells in the lavage fluid of sliced LNs were centrifuged and lysed to extract protein. This extracted protein was used with a low-power and a high-power kit to diagnose LN metastasis. The washed LNs were blindly diagnosed by pathologists using hematoxylin and eosin (H&E) stain. Diagnoses based on the kit were compared with their H&E counterparts.
Results: Of the 159 LNs, 68 were assessed as positive and 91 as negative by permanent pathological examination with H&E. Sensitivity, specificity, and accuracy of the low-power kit for detecting LN metastases was 83.8%, 100%, and 93.1%, respectively. In 11 false-negative cases, there were nine micrometastases, producing a sensitivity of 96.4% for detecting macrometastases. Sensitivity, specificity, and accuracy of the high-power kit for detecting LN metastases was 92.6%, 92.3%, and 92.5%, respectively. Combining the low- and high-power kit results, sensitivity, specificity and accuracy for distinguishing macrometastases from micrometastases was 94.5%, 95.2%, and 95.0%, respectively. Diagnosis was achieved in approximately 20 min using the kits, at a cost of less than 25 USD.
Conclusions: The kits in our study were accurate, quick, and cost-effective in diagnosing LN metastases without the loss of LN tissue. The kits' ability to distinguish macrometastases from micrometastases was excellent, which is important, clinically.
Citation Format: Otsubo R, Hirakawa H, Oikawa M, Inamasu E, Baba M, Matsumoto M, Yano H, Kinoshita N, Abe K, Fukuoka J, Nagayasu T. Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-01-31.
Collapse
Affiliation(s)
- R Otsubo
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - H Hirakawa
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - M Oikawa
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - E Inamasu
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - M Baba
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - M Matsumoto
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - H Yano
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - N Kinoshita
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - K Abe
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - J Fukuoka
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| | - T Nagayasu
- Nagasaki University Hospital, Nagasaki, Japan; Chiba Aiyuukai Memorial Hospital, Chiba, Japan; Nyuuwakai Oikawa Hospital, Fukuoka, Japan
| |
Collapse
|
36
|
Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. Abstract P4-21-03: A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
As for the HER2-positive breast cancer, there are many cases to be effective for neoadjuvant chemotherapy in comparison with other intrinsic subtypes. However, pCR is not provided by neoadjuvant chemotherapy in all cases. [Aim] This study evaluated the effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, relative to that of standard chemotherapy in patients with HER2-positive breast cancer. [patients and methods] Patients were randomly assigned to the control arm or the Ki-67 response-guided arm (Ki-67 arm). Primary tumor biopsies were obtained before treatment, and after three once-weekly doses of paclitaxel and trastuzumab to assess the interim Ki-67 index. In the control arm, paclitaxel and trastuzumab was continued for a total of 12 doses, regardless of the interim Ki-67 index. In the Ki-67 arm, subsequent treatment was based on the interim Ki-67 index. Early Ki-67 responders continued to received paclitaxel plus trastuzumab for a total of 12 doses, while early Ki-67 non-responders were switched to epirubicin plus cyclophosphamide every 3 weeks for three cycles with once-weekly trastuzumab for a total of 12 doses. The primary endpoint was the pathological complete response (pCR) rate. [Results] When 237 patients were enrolled, an interim analysis was conducted in 200 patients. There was almost linear correlation between the Ki-67 reduction rate at interim assessment and the pCR rate. The pCR rate in Ki-67 early non-responders in the Ki-67 arm (23.6%; 95% CI, 12.4 to 34.9) was inferior to that in the control arm (44.1%; 31.4 to 56.7; p=0.025). A strong correlation was not found between the Ki-67 reduction rate and the clinical response rate (Spearman's correlation coefficient 0.22).
pCR rate among Ki-67 early non-responders and responders TotalpCR nn%95%CIKi-67 early non responderControl arm59264431.4-56.7 Ki-67 response guided arm55132312.4-34.9Ki-67 early responderControl arm21104726.3-69.0 Ki-67 response guided arm2084018.5-61.5
Conclusions: The pCR rate in the Ki-67 arm was inferior to that in the control arm. A therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, was not effective. The standard chemotherapy protocol remains as the recommended strategy for patients with HER2-positive breast cancer.
Citation Format: Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-03.
Collapse
Affiliation(s)
- M Takahashi
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - Y Nishiyama
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - F Hara
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - Y Naito
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - M Baba
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - M Sasaki
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - M Sato
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - K Watanabe
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - Y Uemura
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - T Yamaguchi
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| | - H Mukai
- NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; Kumamoto Shinto General Hospital, Kumamoto, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; National Cancer Center Hospital East, Kashiwa, Chiba, Japan; University of Tokyo, Tokyo, Japan; Musashino Red Cross Hospital, Musashino, Tokyo, Japan
| |
Collapse
|
37
|
Gauci MO, Boileau P, Baba M, Chaoui J, Walch G. Patient-specific glenoid guides provide accuracy and reproducibility in total shoulder arthroplasty. Bone Joint J 2017; 98-B:1080-5. [PMID: 27482021 DOI: 10.1302/0301-620x.98b8.37257] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 03/08/2016] [Indexed: 11/05/2022]
Abstract
AIMS Patient-specific glenoid guides (PSGs) claim an improvement in accuracy and reproducibility of the positioning of components in total shoulder arthroplasty (TSA). The results have not yet been confirmed in a prospective clinical trial. Our aim was to assess whether the use of PSGs in patients with osteoarthritis of the shoulder would allow accurate and reliable implantation of the glenoid component. PATIENTS AND METHODS A total of 17 patients (three men and 14 women) with a mean age of 71 years (53 to 81) awaiting TSA were enrolled in the study. Pre- and post-operative version and inclination of the glenoid were measured on CT scans, using 3D planning automatic software. During surgery, a congruent 3D-printed PSG was applied onto the glenoid surface, thus determining the entry point and orientation of the central guide wire used for reaming the glenoid and the introduction of the component. Manual segmentation was performed on post-operative CT scans to compare the planned and the actual position of the entry point (mm) and orientation of the component (°). RESULTS The mean error in the accuracy of the entry point was -0.1 mm (standard deviation (sd) 1.4) in the horizontal plane, and 0.8 mm (sd 1.3) in the vertical plane. The mean error in the orientation of the glenoid component was 3.4° (sd 5.1°) for version and 1.8° (sd 5.3°) for inclination. CONCLUSION Pre-operative planning with automatic software and the use of PSGs provides accurate and reproducible positioning and orientation of the glenoid component in anatomical TSA. Cite this article: Bone Joint J 2016;98-B:1080-5.
Collapse
Affiliation(s)
- M O Gauci
- Hôpital Pasteur 2, 30 Voie Romaine, Nice, 06000, France
| | - P Boileau
- Hôpital Pasteur 2, 30 Voie Romaine, Nice, 06000, France
| | - M Baba
- Specialty Orthopaedics, Sydney, Australia
| | - J Chaoui
- Telecom Brittany, 655 Avenue du Technopole, 29200 Plouzané, France
| | - G Walch
- Centre Orthopédique Santy, Unité Epaule, 24 Avenue Paul Santy, 69008 Lyon, France
| |
Collapse
|
38
|
Uneno Y, Baba M, Kanai M, Taneishi K, Nakatsui M, Okuno Y, Muto M, Morita T. 484O_PR Validation of the set of six adaptable prognosis prediction (SAP) models for cancer patients in palliative care settings: A sub analysis of the Japan-prognostic assessment tools validation (J-ProVal) study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Tanaka H, Walker RT, Hopkins AL, Ren J, Jones EY, Fujimoto K, Hayashi M, Miyasaka T, Baba M, Stammers DK, Stuart DI. Allosteric Inhibitors against HIV-1 Reverse Transcriptase: Design and Synthesis of MKC-442 Analogues Having an Ω-Functionalized Acyclic Structure. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029800900404] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Based on X-ray crystallographic analysis of MKC-442/human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) complex, analogues in which the N1-substituent is replaced with ω-functionalized alkyl groups were designed to improve the affinity for the enzyme. Synthesis of these compounds was carried out starting from MKC-442 by a sequence of reactions (N3-protection, removal of N1-ethoxymethyl group, alkylation, and N3-deprotection). The compounds were evaluated for anti-HIV activity. Structure–activity relationships are discussed in terms of the possible interaction with the enzyme.
Collapse
Affiliation(s)
- H Tanaka
- School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan
| | - RT Walker
- School of Chemistry, The University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - AL Hopkins
- The Laboratory of Molecular Biophysics, Rex Richards Building, South Parks Road, Oxford OX1 3QU, UK
| | - J Ren
- The Laboratory of Molecular Biophysics, Rex Richards Building, South Parks Road, Oxford OX1 3QU, UK
| | - EY Jones
- The Laboratory of Molecular Biophysics, Rex Richards Building, South Parks Road, Oxford OX1 3QU, UK
- The Oxford Centre for Molecular Sciences, New Chemistry Building, South Parks Road, Oxford OX1 3QT, UK
| | - K Fujimoto
- School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan
| | - M Hayashi
- School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan
| | - T Miyasaka
- School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan
| | - M Baba
- Division of Human Retroviruses, Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Kagoshima 890, Japan
| | - DK Stammers
- The Laboratory of Molecular Biophysics, Rex Richards Building, South Parks Road, Oxford OX1 3QU, UK
| | - DI Stuart
- The Laboratory of Molecular Biophysics, Rex Richards Building, South Parks Road, Oxford OX1 3QU, UK
- The Oxford Centre for Molecular Sciences, New Chemistry Building, South Parks Road, Oxford OX1 3QT, UK
| |
Collapse
|
40
|
Oyero OG, Toyama M, Mitsuhiro N, Onifade AA, Hidaka A, Okamoto M, Baba M. SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A NIGELLA SATIVA SEED FORMULATION. Afr J Tradit Complement Altern Med 2016; 13:144-148. [PMID: 28480371 PMCID: PMC5412185 DOI: 10.21010/ajtcam.v13i6.20] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Background: Hepatitis C virus (HCV) infection became curable because of the development of direct acting antivirals (DAAs). However, the high cost of DAAs has greatly impeded their potential impact on the treatment of HCV infection. As a result, hepatitis C will continue to cause substantial morbidity, and mortality among chronically infected individuals in low and middle income countries. Thus, urgent need exists for developing cheaper drugs available to hepatitis C patients in these countries. Materials and Methods: Alpha-zam, an indigenous herbal formulation from Nigella sativa seed, was examined for its anti-HCV activity and cytotoxicity in genotype 1b HCV replicon cells. The antiviral activity was determined by luciferase expression and viral RNA synthesis, while the cytotoxicity was assessed by viable cell number and glyceraldehyde-3-phosphate dehydrogenase RNA synthesis in the replicon cells. Results: Alpha-zam was found to be a selective inhibitor of HCV replication. The 50% effective dilution and 50% cytotoxic dilution of Alpha-zam were 761- and < 100-fold, respectively, in the subgenomic replicon cells LucNeo#2. Its selective inhibition of HCV was also confirmed by HCV RNA levels in LucNeo#2 and in the full-genome HCV replicon cells NNC#2 using real-time reverse transcriptase polymerase chain reaction. Furthermore, the anti-HCV activity of Alpha-zam was not due to the induction of interferon. Conclusion: Alpha-zam selectively inhibits HCV replication and therefore has potential for a novel antiviral agent against HCV infection.
Collapse
Affiliation(s)
- Olufunmilayo G Oyero
- Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, Japan
| | - Naoki Mitsuhiro
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, Japan
| | | | - Akemi Hidaka
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, Japan
| | - Mika Okamoto
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, Japan
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Kagoshima University, Kagoshima, Japan
| |
Collapse
|
41
|
Ito W, Toyama M, Okamoto M, Ikeda M, Watashi K, Wakita T, Hashimoto Y, Baba M. Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative. Antivir Chem Chemother 2016; 24:148-154. [PMID: 27503576 DOI: 10.1177/2040206616663956] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The novel phenanthridinone derivative HA-719 has recently been identified as a highly potent and selective inhibitor of hepatitis C virus replication. To elucidate its mechanism of inhibition, we have isolated and analyzed a clone of hepatitis C virus replicon cells resistant to HA-719. METHODS To isolate HA-719-resistant replicon cells, Huh-7 cells containing subgenomic hepatitis C virus replicons (genotype 1b) with a luciferase reporter (LucNeo#2) were cultured in the presence of G418 and escalating concentrations of HA-719. After several passages, total RNA was extracted from the growing cells, and Huh-7 cells were transfected with the extracted RNA. Limiting dilution of the transfected cells was performed to obtain an HA-719-resistant clone. RESULTS The 50% effective concentration (EC50) of HA-719 for hepatitis C virus replication was 0.058 ± 0.012 µM in LucNeo#2 cells. The replicon cells capable of growing in the presence of G418 and 3 µM HA-719 were obtained after 18 passages (72 days). The HA-719-resistant clone LucNeo719R showed 98.3-fold resistant to the compound (EC50 = 5.66 ± 0.92 µM), but the clone had no cross-resistance to telaprevir (NS3 inhibitor), daclatasvir (NS5A inhibitor), and VX-222 (NS5B inhibitor). The sequence analysis for the wild-type and LucNeo719R identified 3, 2 and 7 mutations in NS3/4 A, NS4B, and NS5A, respectively, but no mutations in NS5B. CONCLUSION None of the amino acid mutations in the resistant clone corresponds to those reported to confer drug-resistance to current anti-hepatitis C virus agents, suggesting that the target of HA-719 for hepatitis C virus inhibition differs from those of the existing agents.
Collapse
Affiliation(s)
- Wataru Ito
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Masaaki Toyama
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Mika Okamoto
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Masanori Ikeda
- 2 Division of Persistent and Oncogenic Viruses, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Koichi Watashi
- 3 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
| | - Takaji Wakita
- 3 Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan
| | - Yuichi Hashimoto
- 4 Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan
| | - Masanori Baba
- 1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| |
Collapse
|
42
|
Kasula M, Toyama M, Samunuri R, Rozy F, Yadav M, Bal C, Jha AK, Baba M, Sharon A. Synthesis and anti-HBV activity of α-stereoisomer of aristeromycin based analogs. Bioorg Med Chem Lett 2016; 26:3945-9. [PMID: 27426303 DOI: 10.1016/j.bmcl.2016.07.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 06/30/2016] [Accepted: 07/02/2016] [Indexed: 10/21/2022]
Abstract
The potential antiviral activity of aristeromycin type of derivatives (I) is limited by associated toxicity due to its possible 5'-O-phosphorylation and S-adenosyl-l-homocysteine hydrolase (SAHase) inhibitory activity. Aristeromycin structure has major pharmacophoric motif as 5'-OH and adenosine base, which may have significant role in enzyme binding followed by activity and or toxicity. Thus, the structural optimization to alter this major motif by replacing with its bioisostere and changing the 5'-O conformation through stereochemistry reversal was of interest. Thus, the inverted stereochemistry at 4'-position coupled with bioisostere of adenosine base in the target compounds (6-7) to access antiviral potential. The stereoselective formation of a key stereoisomer (2a) was achieved exclusively from neplanocin sugar (1a) by reduction in a single step. The novel target molecules (6-7) were synthesized in 4 steps with 55-62% yield. Compound 6 was analyzed by single crystal X-ray diffraction, which confirms the stereoselective formation of α-analogs with highly puckered cyclopentane ring and 2'-endo conformation. The compound 6 shown significant anti-hepatitis B virus activity of 6.5μM with CC50>100μM and yielded a promising lead with novel structural feature.
Collapse
Affiliation(s)
- Mohan Kasula
- Department of Chemistry, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Masaaki Toyama
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima 890-8544, Japan
| | | | - Farhana Rozy
- Department of Chemistry, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Monika Yadav
- Department of Chemistry, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Chandralata Bal
- Department of Chemistry, Birla Institute of Technology, Mesra, Ranchi 835215, India
| | - Ashok Kumar Jha
- Chemistry Services, GVK Biosciences Pvt, Ltd, IDA Uppal, Hyderabad 500039, India
| | - Masanori Baba
- Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima 890-8544, Japan
| | - Ashoke Sharon
- Department of Chemistry, Birla Institute of Technology, Mesra, Ranchi 835215, India
| |
Collapse
|
43
|
Tárkányi F, Ditrói F, Takács S, Hermanne A, Baba M. Activation cross sections of proton and deuteron induced nuclear reactions on holmium and erbium, related to the production of (161)Er and (160)Er medical isotopes. Appl Radiat Isot 2016; 115:262-266. [PMID: 27451109 DOI: 10.1016/j.apradiso.2016.07.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Revised: 06/17/2016] [Accepted: 07/05/2016] [Indexed: 10/21/2022]
Abstract
Experimental excitation functions for long-lived products in proton induced reactions were measured with the activation method in the 37-65MeV energy range on natural holmium. Stacked foil irradiation technique and high resolution gamma spectrometry were used in order to measure cross-section data for the production of (161)Er, (160)Er and (1)(59,157)Dy. For comparison of the production routes of medically related (161)Er and (160)Er radioisotopes new experimental cross section data were deduced for the (162)Er(p,x)(161,160)Er and (162)Er(d,x)(161,160)Er reactions by re-evaluating gamma-ray spectra from earlier measurements. No earlier data were found in the literature for these reactions. The experimental data are compared with results of TALYS theoretical code reported in TENDL-2015.
Collapse
Affiliation(s)
- F Tárkányi
- Institute for Nuclear Research, Hungarian Academy of Sciences (ATOMKI), 4026 Debrecen, Hungary
| | - F Ditrói
- Institute for Nuclear Research, Hungarian Academy of Sciences (ATOMKI), 4026 Debrecen, Hungary.
| | - S Takács
- Institute for Nuclear Research, Hungarian Academy of Sciences (ATOMKI), 4026 Debrecen, Hungary
| | - A Hermanne
- Vrije Universiteit Brussel (VUB), Cyclotron Laboratory, 1090 Brussels, Belgium
| | - M Baba
- Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai 980-8578, Japan
| |
Collapse
|
44
|
Miyata K, Mohri K, Egawa T, Endo R, Morimoto N, Ochiai K, Hiwatari KI, Tsubaki K, Tobita E, Uto T, Baba M, Sakuma S. Demonstration of d-Octaarginine-Linked Polymers as Promising Adjuvants for Mucosal Vaccination through Influenza Virus Challenge. Bioconjug Chem 2016; 27:1865-71. [DOI: 10.1021/acs.bioconjchem.6b00283] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Kohei Miyata
- Faculty
of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
- Life
Science Materials Laboratory, ADEKA Co., 7-2-34 Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Kohta Mohri
- Faculty
of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Tomomi Egawa
- Faculty
of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Rikito Endo
- Faculty
of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Naoki Morimoto
- Life
Science Materials Laboratory, ADEKA Co., 7-2-34 Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Kyohei Ochiai
- Life
Science Materials Laboratory, ADEKA Co., 7-2-34 Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Ken-ichiro Hiwatari
- Life
Science Materials Laboratory, ADEKA Co., 7-2-34 Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Kazufumi Tsubaki
- Life
Science Materials Laboratory, ADEKA Co., 7-2-34 Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Etsuo Tobita
- Life
Science Materials Laboratory, ADEKA Co., 7-2-34 Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Tomofumi Uto
- School
of Medicine, Miyazaki University, Kihara 5200 Kiyotake-cho, Miyazaki, Miyazaki 889-1692, Japan
| | - Masanori Baba
- Graduate
School of Medical and Dental Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, Kagoshima 890-8544, Japan
| | - Shinji Sakuma
- Faculty
of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| |
Collapse
|
45
|
Mohan P, Hopfinger AJ, Baba M. Naphthalenesulphonic Acid Derivatives as Potential anti-HIV-1 Agents. Chemistry, Biology and Molecular Modelling of Their Inhibition of Reverse Transcriptase. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029100200402] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Activity against human immunodeficiency virus (HIV) in the naphthalenesulphonic acid series is most pronounced in the disulphonic acid series. In this class of compounds, N-acyl derivatives of 4-amino-5-hydroxy-2,7-naphthalenedisulphonic acid demonstrate significant anti-HIV activity at non-toxic doses. The most potent compounds in this group of agents are bis naphthalenedisulphonic acids. A bis derivative containing a decamethylene spacer demonstrated activity against HIV-1, HIV-2 giant cell formation and reverse transcriptase (RT). This compound also demonstrated an in vitro therapeutic index (ratio of 50% cytotoxic concentration to 50% inhibitory antiviral concentration) of 10.6. Molecular modelling analyses of this agent, suramin, and several suramin analogues were undertaken to explain the potent anti-HIV-1 RT activity. These studies were carried out using the molecular decomposition/recomposition strategy, conformational searching, energy minimization and molecular dynamics (MD) simulation. The bis naphthalenedisulphonic acid derivative compound 1, having a flexible decamethylene spacer, was shown to be able to mimic the helical twist of the B-DNA backbone as a low energy conformer state.
Collapse
Affiliation(s)
- P. Mohan
- Department of Medicinal Chemistry and Pharmacognosy (M/C 781), College of Pharmacy, University of Illinois at Chicago, Box 6998, Chicago, IL 60680, USA
| | - A. J. Hopfinger
- Department of Medicinal Chemistry and Pharmacognosy (M/C 781), College of Pharmacy, University of Illinois at Chicago, Box 6998, Chicago, IL 60680, USA
| | - M. Baba
- Department of Microbiology, Fukushima Medical College, Hikarigaoka 1, Fukushima 960-12, Japan
| |
Collapse
|
46
|
Schols D, De Clercq E, Balzarini J, Baba M, Witvrouw M, Hosoya M, Andrei G, Snoeck R, Neyts J, Pauwels R, Nagy M, Györgyi-Edelényi J, Machovich R, Horváth I, Low M, Görög S. Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029000100402] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The sulphated polymers, such as polyvinylalcohol sulphate (PVAS) and its co-polymer with acrylic acid (PAVAS), have proved to be potent inhibitors for herpes simplex virus, human cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, Sindbis virus, Semliki Forest virus, Junin virus, Tacaribe virus, murine sarcoma virus and human immunodeficiency virus. They are not inhibitory to non-enveloped viruses, such as poliovirus and reovirus. The broad-spectrum antiviral effects of these compounds depend on their molecular weight and degree of sulphation. Pharmacokinetic studies in rabbits have indicated that after intravenous bolus injection the serum concentrations of these compounds decay biphasically, with an initial half-life of approximately 90–120 min.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - M. Nagy
- Department of Colloid Science, Eötvös Loránd University, Budapest, Hungary
| | | | - R. Machovich
- 2nd Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
| | - I. Horváth
- 2nd Institute of Biochemistry, Semmelweis University Medical School, Budapest, Hungary
| | - M. Low
- Chemical Works of Gedeon Richter Ltd, Budapest, Hungary
| | - S. Görög
- Chemical Works of Gedeon Richter Ltd, Budapest, Hungary
| |
Collapse
|
47
|
Hashimoto K, Kodama E, Mori S, Watanabe J, Baba M, Okutani K, Matsuda M, Shigeta S. Antiviral Activity of a Sulphated Polysaccharide Extracted from the Marine Pseudomonas and Marine Plant Dinoflagellata against Human Immunodeficiency Viruses and other Enveloped Viruses. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029600700403] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A natural sulphated mucopolysaccharide (OKU40), extracted from a marine plant Dinoflagellata, and an artificial sulphated polysaccharide (OKU41), prepared from a marine Pseudomonas, displayed antiviral activities against several enveloped viruses. OKU40 and OKU41 were found to be homogenous in electrophoresis and sedimation velocity and had a molecular weight of 8.0 × 1065.0 × 105respectively. The sulphation rate of OKU40 and OKU41 was 8.9% and 5.4%, respectively. Each OKU40 and OKU41 inhibited the cytopathic effect of human immunodeficiency virus type 1 (HIV-1), type 2 (HIV-2) and zidovudineresistant HIV-1 in MT-4 cells at similar concentrations to those of dextran sulphate (molecular weight: 5000) (50% inhibitory concentrations: 0.86-1.95 μg mL−1), whereas these compounds did not affect the growth and viability of mock-infected MT-4 cells at concentrations up to 500 μg mL−1. These compounds proved inhibitory not only to HIV-1 and HIV-2 but also to other enveloped viruses, i.e. herpes simplex virus type 1, influenza virus A and B, respiratory syncytial virus and measles virus. OKU40 and OKU41 suppressed syncytium formation induced by cocultivation of MOLT-4/IIIb and MOLT-4 cells at concentrations higher than 20 μg mL−1. Although OKU41 inhibited the binding of HIV-1 to the host cells and the binding of anti-gp120 monoclonal antibody to HIV-1 gp120, OKU40 did not inhibit these bindings, suggesting that the mechanism of anti-HIV activity of OKU40 and OKU41 may be primarily due to the inhibition of virus-cell fusion and viral adsorption to the host cells, respectively. Furthermore, these compounds did not inhibit to the blood coagulation process at a concentration that was significantly inhibitory to HIV replication. The compounds appear to have an interesting potential as virucidal agents.
Collapse
Affiliation(s)
- K. Hashimoto
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - E. Kodama
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - S. Mori
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - J. Watanabe
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - M. Baba
- Division of Human Retroviruses, Centre for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Kagoshima 890, Japan
| | - K. Okutani
- Faculty of Agriculture, Kagawa University, Kagawa 761-07, Japan
| | - M. Matsuda
- Faculty of Agriculture, Kagawa University, Kagawa 761-07, Japan
| | - S. Shigeta
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| |
Collapse
|
48
|
Shigeta S, Mori S, Baba M, Hosoya M, Mochizuki N, Chiba T, De Clercq E. Inhibitory Effect of Pyridobenzoazoles on Orthomyxo-and Paramyxovirus Replication in vitro. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029200300307] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Among thirteen newly synthesized pyridobenzoazole derivatives which have been examined for anti-myxovirus and antiherpesvirus activities, three benzimidazoles emerged as potent anti-orthomyxo- or paramyxovirus compounds. 4-Cyano-2-benzamide-1-oxo-1,5-dihydropyrido[1,2a]benzimidazole (CBO-PB) showed broad antiviral activities against paramyxo-and orthomyxoviruses with EC50 of 0.1–2.0 μg ml−1, and 2-cyano-1-amino derivatives of CBO-PB (CCI-PB) were inhibitory to paramyxoviruses at 1.4–8.5 (μg ml−1 by a plaque reduction method. The third compound, 2-ethoxycarbonyl derivatives of CCI-PB was inhibitory only to respiratory syncytial virus (RSV) at 15–28 μg ml−1. Selectivity indexes of these 3 compounds for RSV in HeLa cells were 60, 86, and >13, respectively. All three compounds inhibited syncytium formation of RSV and Parainfluenzavirus (PFLUV) type 3 at comparable concentrations with EC50 for plaque formation. They inhibited antigen production of RSV and PFLUV at the concentrations that were 4 to 20-fold higher than those needed for plaque reduction, but they did not inhibit adsorption of virus to cells at all. All three compounds inhibited the growth of RSV in HeLa cells at 4-fold higher concentrations than their EC50 for plaque reduction.
Collapse
Affiliation(s)
- S. Shigeta
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - S. Mori
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - M. Baba
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - M. Hosoya
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - N. Mochizuki
- Department of Microbiology, Fukushima Medical College, Fukushima 960-12, Japan
| | - T. Chiba
- Pharmaceutical Institute, Tohoku University, Sendai 980, Japan
| | - E. De Clercq
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| |
Collapse
|
49
|
Ito M, Baba M, Shigeta S, Wada S, Takagi M, Kimura T, Okuyama T. Potent and Selective Activity of Dextrin Sulphate against Human Immunodeficiency Virus Type 1 in vitro. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029100200107] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Several dextrin sulphate derivatives were prepared and investigated for their activity against human immunodeficiency virus type 1 (HIV-1) in vitro. These compounds have proved to be potent and selective inhibitors of HIV-1. One of the compounds, termed FG-752 [molecular weight (MW) 3000], was the most active, and its 50% antiviral effective concentration was 2.1 μg ml−1 (0.7 μm) in MT-4 cells. No toxicity for the cells was observed at a concentration of 500 μg ml−1. The compounds were also inhibitory to HIV-1-induced giant cell (syncytium) formation. These results suggest that dextrin sulphate may be useful for the chemotherapy of HIV-1 infections.
Collapse
Affiliation(s)
- M. Ito
- Department of Bacteriology, Fukushima Medical College, Fukushima 960–12, Japan
| | - M. Baba
- Department of Bacteriology, Fukushima Medical College, Fukushima 960–12, Japan
| | - S. Shigeta
- Department of Bacteriology, Fukushima Medical College, Fukushima 960–12, Japan
| | - S. Wada
- Central Research Laboratories, Chugai Pharmaceutical Co Ltd, Toshima-ku, Tokyo 171, Japan
| | - M. Takagi
- Central Research Laboratories, Chugai Pharmaceutical Co Ltd, Toshima-ku, Tokyo 171, Japan
| | - T. Kimura
- Central Research Laboratories, Chugai Pharmaceutical Co Ltd, Toshima-ku, Tokyo 171, Japan
| | - T. Okuyama
- Central Research Laboratories, Chugai Pharmaceutical Co Ltd, Toshima-ku, Tokyo 171, Japan
| |
Collapse
|
50
|
Shigeta S, Mori S, Watanabe J, Baba M, Khenkin AM, Hill CL, Schinazi RF. In vitro Antimyxovirus and Anti-Human Immunodeficiency Virus Activities of Polyoxometalates. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029500600206] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Polyoxometalates have been shown to inhibit the replication of retro-, toga-, paramyxo- and herpesviruses. The primary mechanism of the anti-human immunodeficiency virus type 1 (HIV-1) action of polyoxometalates seems to be inhibition of binding of virus to cells and inhibition of syncytium formation. Since myxoviruses and HIV-1 are known to interact with the cytoplasmic membrane by adsorption and penetration of virus and by fusion of infected and uninfected cells, 25 polyoxometalates were examined for anti-ortho-, anti-paramyxovirus and anti-HIV-1 activity in vitro. Of the 25 compounds evaluated, 24 showed antiviral effects against influenza virus A, 11 showed activity against respiratory syncytial virus, six showed activity against measles virus, and 23 were considered effective against HIV-1 at a lower concentration than that producing cytotoxicity. Four polyoxotungstates which had potent inhibitory effects were examined for inhibitory effects against additional ortho- and paramyxoviruses, and proved to have a broad spectrum of antimyxoviral activity. HS-058, the Keggin sandwich compound K10Fe4(H2O)2(PW9O34)2·nH2O, was inhibitory against influenza viruses A and B, respiratory syncytial virus, measles virus, and parainfluenza virus 2, with median effective concentrations of 1.4, 21.8, 7.4, 0.8 and 0.32 μ,M, respectively. However, HS-058 had no effect on parainfluenza virus 3 or mumps virus. The median cytotoxic concentration of HS-058 for Madin-Darby canine kidney (MDCK) and HEp-2 cells was more than 200 μM and that for HMV-2 and Vero cells was about 50 μM. When HS-058 was added at different times after influenza A and respiratory syncytial virus infection, it inhibited binding of the latter but not of the former to cells. However, at higher concentrations, HS-054 and HS-058 inhibited haemolysis of chick erythrocytes by influenza virus and syncytium formation involving respiratory syncytial virus-infected cells and uninfected cells. Four times the median effective antiviral concentration of HS-058 completely inhibited the growth of influenza virus A in MDCK cells when compound was added before virus adsorption. Furthermore, when HS-058 was added after virus adsorption, it inhibited the yield of virus in MDCK cells infected at low but not at high multiplicity of infection.
Collapse
Affiliation(s)
- S. Shigeta
- Department of Microbiology, Fukushima Medical College, Fukushima, 960-12, Japan
| | - S. Mori
- Department of Microbiology, Fukushima Medical College, Fukushima, 960-12, Japan
| | - J. Watanabe
- Department of Microbiology, Fukushima Medical College, Fukushima, 960-12, Japan
| | - M. Baba
- Department of Microbiology, Fukushima Medical College, Fukushima, 960-12, Japan
| | - A. M. Khenkin
- Department of Chemistry, Emory University, Atlanta, GA 30322, USA
| | - C. L. Hill
- Department of Chemistry, Emory University, Atlanta, GA 30322, USA
| | - R. F. Schinazi
- Department of Pediatrics, Emory University, Atlanta, GA 30322, USA
- Veterans Affairs Medical Center, Medical Research 151, 1670 Clairmont Road, Decatur, GA 30033, USA
| |
Collapse
|